Adi Gazdar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adi Gazdar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Lam
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, Canada
4 shared publications - Calum MacAulay
Basic and Translational Research, BC Cancer Research Institute, 675 West 10th Avenue, Vancouver, BC V5Z Il3, Canada
2 shared publications Chris Dawe
Department of Cancer Imaging, Vancouver, British Columbia, Canada
2 shared publications- Martial Guillaud
Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
2 shared publications Andy Coldman
Department of Cancer Control, Vancouver, British Columbia, Canada
1 shared publication- Annette McWilliams
Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, Canada
1 shared publication
Latest Publications
- 30 January 2010
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 29 (1) , 5-14
Natural history of bronchial preinvasive lesions
Preinvasive bronchial lesions defined as dysplasia and carcinoma in situ (CIS) have been considered as precursors of squamous cell carcinoma of the lung. The risk and rate of progression of preinvasive lesions to invasive squamous cell carcinoma as well as the mechanism of progression or regression are incompletely understood. While the evidence for the multistage, stepwise progression model is weak with relatively few documented lesions that progress through various grades of dysplasia to CIS and then to invasive carcinoma, the concept of field carcinogenesis is strongly supported. The presence of high-grade dysplasia or CIS is a risk marker for lung cancer both in the central airways and peripheral lung. Genetic alterations such as loss of heterozygosity in chromosome 3p or chromosomal aneusomy as well as host factors such as the inflammatory load and levels of anti-inflammatory proteins in the lung influence the progression or regression of preinvasive lesions. CIS is different than severe dysplasia at the molecular level and has different clinical outcome. Molecular analysis of dysplastic lesions that progress to CIS or invasive cancer and rare lesions that progress rapidly from hyperplasia or metaplasia to CIS or invasive cancer will shed light on the key molecular determinants driving development to an invasive phenotype versus those associated with tobacco smoke damage.
- 30 January 2010
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 29 (1) , 5-14
Natural history of bronchial preinvasive lesions
Preinvasive bronchial lesions defined as dysplasia and carcinoma in situ (CIS) have been considered as precursors of squamous cell carcinoma of the lung. The risk and rate of progression of preinvasive lesions to invasive squamous cell carcinoma as well as the mechanism of progression or regression are incompletely understood. While the evidence for the multistage, stepwise progression model is weak with relatively few documented lesions that progress through various grades of dysplasia to CIS and then to invasive carcinoma, the concept of field carcinogenesis is strongly supported. The presence of high-grade dysplasia or CIS is a risk marker for lung cancer both in the central airways and peripheral lung. Genetic alterations such as loss of heterozygosity in chromosome 3p or chromosomal aneusomy as well as host factors such as the inflammatory load and levels of anti-inflammatory proteins in the lung influence the progression or regression of preinvasive lesions. CIS is different than severe dysplasia at the molecular level and has different clinical outcome. Molecular analysis of dysplastic lesions that progress to CIS or invasive cancer and rare lesions that progress rapidly from hyperplasia or metaplasia to CIS or invasive cancer will shed light on the key molecular determinants driving development to an invasive phenotype versus those associated with tobacco smoke damage.
- Open Access
- 21 December 2004
- Published by Wiley in Cytometry Part A
- Vol. 63A (1) , 34-40
Nuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: Correlation with genetic damage and cancer development
- 21 December 2004
- Published by Wiley in Cytometry Part A
- Vol. 63A (1) , 34-40
Open AccessNuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: Correlation with genetic damage and cancer development
- Open Access
- 5 February 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (3) , 243-244
RESPONSE: Re: Sex-Related Differences in Bronchial Epithelial Changes Associated With Tobacco Smoking
There is a sex difference in the distribution of histologic subtypes of lung cancer worldwide (1). In the United States and Canada, squamous cell carcinoma accounts for approximately 37% of the lung cancers in men but only 20% of the lung cancers in women. In Europe, a similar sex difference was observed (approximately 47% in men versus 27% in women). We discussed in our previous report that “in women, the major histologic lung cancer cell type found is adenocarcinoma, whereas, until recently, in men the predominant cell type was squamous cell carcinoma… . Most adenocarcinomas arise from epithelial cells in the peripherally located bronchi, bronchioles, and alveoli that are beyond the range of an adult-size fiberoptic bronchoscope” (2). The lower prevalence of preinvasive bronchial lesions in the central airways of women (14% versus 31% in men), most of which are precursors of squamous cell carcinoma, closely reflects reality. In our updated, larger cohort of 721 smokers older than 45 years, a similar, statistically significant sex difference in the prevalence of preinvasive lesions was observed, whether we use our previous definition of preinvasive lesion or the more restrictive definition suggested by Paris et al. (Table 1 ). With our definition, a lower prevalence in women (odds ratio = 0.7) was also observed by Paris et al. Their results confirm our observations, although the differences that they observed did not reach statistical significance, probably because of their skewed study population and comparatively smaller sample size. Although our previous study included only healthy volunteer smokers, Paris et al. included patients with cured invasive lung cancer, patients with synchronous invasive lung cancer, and smokers who were exposed to occupational carcinogens and who had a statistically significantly higher prevalence of preinvasive lesions. By including women who had or were more prone to develop these lesions, it should not be surprising that different results are observed. Furthermore, the sex difference in the prevalence of preinvasive lesions in the central airways is not equivalent to overall cancer risk differences between men and women.
- 5 February 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (3) , 243-244
Open AccessRESPONSE: Re: Sex-Related Differences in Bronchial Epithelial Changes Associated With Tobacco Smoking
There is a sex difference in the distribution of histologic subtypes of lung cancer worldwide (1). In the United States and Canada, squamous cell carcinoma accounts for approximately 37% of the lung cancers in men but only 20% of the lung cancers in women. In Europe, a similar sex difference was observed (approximately 47% in men versus 27% in women). We discussed in our previous report that “in women, the major histologic lung cancer cell type found is adenocarcinoma, whereas, until recently, in men the predominant cell type was squamous cell carcinoma… . Most adenocarcinomas arise from epithelial cells in the peripherally located bronchi, bronchioles, and alveoli that are beyond the range of an adult-size fiberoptic bronchoscope” (2). The lower prevalence of preinvasive bronchial lesions in the central airways of women (14% versus 31% in men), most of which are precursors of squamous cell carcinoma, closely reflects reality. In our updated, larger cohort of 721 smokers older than 45 years, a similar, statistically significant sex difference in the prevalence of preinvasive lesions was observed, whether we use our previous definition of preinvasive lesion or the more restrictive definition suggested by Paris et al. (Table 1 ). With our definition, a lower prevalence in women (odds ratio = 0.7) was also observed by Paris et al. Their results confirm our observations, although the differences that they observed did not reach statistical significance, probably because of their skewed study population and comparatively smaller sample size. Although our previous study included only healthy volunteer smokers, Paris et al. included patients with cured invasive lung cancer, patients with synchronous invasive lung cancer, and smokers who were exposed to occupational carcinogens and who had a statistically significantly higher prevalence of preinvasive lesions. By including women who had or were more prone to develop these lesions, it should not be surprising that different results are observed. Furthermore, the sex difference in the prevalence of preinvasive lesions in the central airways is not equivalent to overall cancer risk differences between men and women.
- 29 April 1998
- Published by SPIE-Intl Soc Optical Eng
- Vol. 3260, 207-212
Intermediate endpoint biomarkers for lung cancer chemoprevention
Given the demographics of current and ex-smoking populations in North America, lung cancer will be a major problem in the foreseeable future. Early detection and treatment of lung cancer holds great promise for the management of this disease. Unlike cervical cancer, the physical, complete removal/destruction of all dysplastic lesions in the bronchial tree is not possible; however, treatment of the lesions using a chemopreventive agent is. Intermediate biomarkers have been used to screen promising chemopreventive agents for larger population studies. We have examined the natural history of lung cancer development by following a group of subjects at high risk of developing lung cancer using fluorescence endoscopy to identify the areas of abnormality for biopsy. Approximately 900 biopsies have been collected in this fashion and graded by at least two experienced, expert pathologists. Using an interactive version of the Cyto-Savant (Oncometrics Imaging Corp.), cytometric and tissue architectural data were collected from these biopsies. Using only the data from the normal and invasive cancer biopsies, quantitative morphometric and architectural indices were generated and calculated for all the collected biopsies. These indices were compared with Loss of Heterozygosity (LOH) of ten sites commonly associated with cancer. These results and the application of these quantitative measures to two small chemoprevention studies will be reported.
- 29 April 1998
- Published by SPIE-Intl Soc Optical Eng
- Vol. 3260, 207-212
Intermediate endpoint biomarkers for lung cancer chemoprevention
Given the demographics of current and ex-smoking populations in North America, lung cancer will be a major problem in the foreseeable future. Early detection and treatment of lung cancer holds great promise for the management of this disease. Unlike cervical cancer, the physical, complete removal/destruction of all dysplastic lesions in the bronchial tree is not possible; however, treatment of the lesions using a chemopreventive agent is. Intermediate biomarkers have been used to screen promising chemopreventive agents for larger population studies. We have examined the natural history of lung cancer development by following a group of subjects at high risk of developing lung cancer using fluorescence endoscopy to identify the areas of abnormality for biopsy. Approximately 900 biopsies have been collected in this fashion and graded by at least two experienced, expert pathologists. Using an interactive version of the Cyto-Savant (Oncometrics Imaging Corp.), cytometric and tissue architectural data were collected from these biopsies. Using only the data from the normal and invasive cancer biopsies, quantitative morphometric and architectural indices were generated and calculated for all the collected biopsies. These indices were compared with Loss of Heterozygosity (LOH) of ten sites commonly associated with cancer. These results and the application of these quantitative measures to two small chemoprevention studies will be reported.